Immunocore Holdings plc Cash And Cash Equivalents
Immunocore Holdings plc (IMCR) had Cash And Cash Equivalents of GBP 342.34 million as of 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Balance Sheet › Assets
ifrs-full:CashAndCashEquivalents · last filed 2023-08-10
- 2023-06-30: Cash And Cash Equivalents 342.34M GBP.
- 2022-12-31: Cash And Cash Equivalents 332.54M GBP.
- 2022-09-30: Cash And Cash Equivalents 347.19M GBP.
- 2022-06-30: Cash And Cash Equivalents 208.06M GBP.
| Period end | Cash And Cash Equivalents |
|---|---|
| 2023-06-30 | 342.34M GBP 6-K · filed 2023-08-10 |
| 2022-12-31 | 332.54M GBP 6-K · filed 2023-08-10 |
| 2022-09-30 | 347.19M GBP 6-K/A · filed 2022-11-18 |
| 2022-06-30 | 208.06M GBP 6-K · filed 2023-08-10 |
| 2021-12-31 | 237.89M GBP 6-K · filed 2023-08-10 |
| 2021-09-30 | 256.55M GBP 6-K/A · filed 2022-11-18 |
| 2020-12-31 | 129.72M GBP 20-F · filed 2023-03-01 |
| 2019-12-31 | 73.97M GBP 20-F · filed 2023-03-01 |
| 2018-12-31 | 124.39M GBP 20-F · filed 2022-03-03 |
| 2017-12-31 | 82.88M GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |